Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Injection in Metastatic or Recurrent Solid Tumors
NCT06088472Phase 1Active, not recruiting
- Sponsor
- Grit Biotechnology
- Start
- Apr 2021
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MDA-TIL in solid tumor, sponsored by Grit Biotechnology. Primary endpoint: Adverse Events at 24 weeks. Started Apr 2021; status: active, not recruiting.
02
Drugs
MDA-TIL
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06088472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06088472.